Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
Investopedia on MSN16h
Novo Nordisk Stock Slips as Sales Grow Less Than ExpectedAfter rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...
Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk ...
Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1 ...
CBS News on MSN3d
Novo Nordisk's obesity-fighting drugs are fattening Denmark's economy while shrinking other sectorsNovo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
CNBC on MSN1d
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidanceNovo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...
Cervecerias Unidas shares have fallen 12% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $11, a decrease of 6% in the last 12 months. This story was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback